SCHEMBL1471652

SCHEMBL1471652

Cc1ccc(C2=CC(=O)N(c3cccc(C)c3)C2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.54
MGLL Q99685 1/20 0.54
L3MBTL1 Q9Y468 3/20 0.49
RGS4 P49798 1/20 0.47
ALDH1A1 P00352 5/20 0.43
MAPT P10636 4/20 0.43
GAA P10253 3/20 0.43
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HTT P42858 2/20 0.43
CCR6 P51684 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CASP6 P55212 1/20 0.43
HSD17B10 Q99714 1/20 0.42
MAPK1 P28482 2/20 0.42
CACNA1B Q00975 2/20 0.42
APBA1 Q02410 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471845 0.91 HSP90AA1 (0.54) HSP90AA1MGLLL3MBTL1RGS4ALDH1A1
SCHEMBL1471125 0.90 HSP90AA1 (0.50) HSP90AA1MGLLL3MBTL1RGS4ALDH1A1
SCHEMBL1473671 0.88 MGLL (0.51) HSP90AA1MGLLL3MBTL1RGS4ALDH1A1
SCHEMBL1471051 0.88 MAPT (0.49) HSP90AA1MGLLL3MBTL1RGS4ALDH1A1
SCHEMBL1471536 0.86 RGS4 (0.57) HSP90AA1MGLLRGS4ALDH1A1MAPT
SCHEMBL1471680 0.84 MGLL (0.52) MGLLRGS4ALDH1A1MAPTGAA
SCHEMBL1471186 0.84 CYP1A2 (0.46) RGS4ALDH1A1MAPTNPSR1HTT
SCHEMBL1471120 0.81 MGLL (0.47) HSP90AA1MGLLL3MBTL1ALDH1A1MAPT
SCHEMBL1471189 0.80 ALDH1A1 (0.57) MGLLRGS4ALDH1A1MAPTGAA
SCHEMBL1471071 0.78 GAA (0.48) MGLLRGS4ALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 HSP90AA1 393/4885MGLL 857/4885L3MBTL1 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.